In Section 1, we quote “For instance, by characterizing the presence of breast cancers’ receptors, including ER, PR, HER2 and TNBCs, each subtype will have a higher risk of recurrence than others during particular years or in a specific situation [10,11,12].” This evidence concerns the gene ERBB2 and breast carcinoma.